Sana Biotechnology (NASDAQ:SANA) Price Target Raised to $11.00 at HC Wainwright

Sana Biotechnology (NASDAQ:SANA) had its price target hoisted by HC Wainwright from $8.00 to $11.00 in a research note published on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other analysts have also recently commented on SANA. JMP Securities cut Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th. TD Cowen raised shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $14.25.

Sana Biotechnology Stock Performance

SANA opened at $4.30 on Wednesday. The company’s 50-day simple moving average is $2.39 and its two-hundred day simple moving average is $4.07. The stock has a market capitalization of $960.06 million, a P/E ratio of -3.07 and a beta of 1.45. Sana Biotechnology has a 52-week low of $1.52 and a 52-week high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.01. Research analysts forecast that Sana Biotechnology will post -1.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB purchased a new position in Sana Biotechnology during the third quarter valued at approximately $29,000. Stifel Financial Corp bought a new stake in shares of Sana Biotechnology during the 3rd quarter valued at $43,000. EP Wealth Advisors LLC purchased a new position in shares of Sana Biotechnology during the 3rd quarter valued at $45,000. Blue Trust Inc. boosted its holdings in Sana Biotechnology by 1,246.6% in the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock worth $55,000 after buying an additional 12,154 shares during the period. Finally, Cornercap Investment Counsel Inc. purchased a new stake in Sana Biotechnology in the 3rd quarter worth $67,000. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.